Skip to Content

Illumen Magazine

A project of Hiraeth Books (see other related projects).

About

81 members set this magazine as a Favorite.

Illumen publishes original poems sci-fi and fantasy genres, with some horror. We also include various art, articles, reviews, and interviews. Describe other worlds in poetic prose, challenge heroes and villains with eloquent words, show the nightmare of real life in all its disgusting mud and muck. We want your electric dreams, your fevered nightmares, your tales of magic, the wonder of a new robotic mind, and more.

Country of Publication

United States

Publication Medium & Frequency

Print Publication Print PublicationPublished 4 x per year.

Nonfiction Open

Those who submit articles for consideration have a loose rein on the topic. All we ask is that the article address some aspect of speculative poetry. We like to see reviews of collections of speculative poetry.

Audience:

Open to a broad Audience.

Lengths:
Review Review800 - 1,200 words.
Article Article800 - 2,000 words.
Styles:

Open to all/most Styles, including: Mainstream.

Topics:

Literature/Books (Theory/Analysis/Criticism, See guidelines).

Payment:

Token payment (under 1 US cent per word) to Semi-pro payment (1-4.9 US cents per word) Pay ranges from Token payment to Semi-pro payment. Details: USD $12 for original articles; $5 for reprint articles; $7 for reviews.

Submissions:

Method: Email.
Reprints: Reprints are allowed.
Simultaneous submissions: Unknown.
Media: Text.


Poetry Open

Speculative poetry is one result of the application of imagination to reality. In speculative poetry, one’s “vision” often is taken from a different angle, from another perspective, perhaps even from another time and place. Speculative poetry is usually tinged with one or more of the genres. Thus, in speculative poetry you find hints of science fiction, fantasy, folklore, myth, the surreal…and yes, even horror. Good speculative poetry will awaken a sense of adventure in the reader. That’s what we’re looking for: good, original speculative poetry.

Audience:

Open to a broad Audience.

Genres:
GenreSubgenres
Fantasy FantasyOpen to all/most Subgenres, including: Slipstream.
Horror HorrorOpen to all/most Subgenres, including: Slipstream.
Science Fiction Science FictionOpen to all/most Subgenres, including: Slipstream.
Lengths:
Poem Poem12 - 100 lines; Unknown number of pieces.
Poetry Forms:

Open to all/most Forms.

Styles:

Open to all/most Styles, including: Literary, Mainstream, Surrealist.

Topics:

Open to all/most Topics.

Payment:

Token payment (under US$5 per poem) to Semi-pro payment (US$5-49 per poem) Pay ranges from Token payment to Semi-pro payment. Details: USD $0.02/word, $3 minimum. $0.01 for reprints. $1 for Scifaiku and related forms. $15 for Featured Poet.

Submissions:

Method: Email.
Reprints: Reprints are allowed.
Simultaneous submissions: Unknown.
Media: Text.


Visual Art Open

Illustrations should complement the speculative aspects of the poetry. We use both color and black and white illustrations, both interior and on the cover. We suggest a minimalist approach to illustrations: less is more. Greatly detailed illustrations can distract from the poetry. We’ll consider both original and reprint illustrations.

Audience:

Open to a broad Audience.

Lengths:
Artwork Artwork2 - 3 pieces.
Art Media:

Illustration.

Art Styles:

Open to all/most Art Styles, including: Fantastical, Minimalist, Science fiction art.

Topics:

Open to all/most Topics.

Payment:

Token payment (under US$10 per piece) Token payment. Details: USD $5 for original illustrations; $3 for reprints; $12 for cover art.

Submissions:

Method: Email.
Reprints: Reprints are allowed.
Simultaneous submissions: Unknown.
Media: Image.


Always check guidelines for details and restrictions. If you aren't familiar with these terms, see our glossary.

Illumen Magazine Submission Statistics — Free Preview!

The statistics in this section are compiled from submission reports sent to us through our submission tracker. They are not provided by the publication's editors/staff or by Duotrope's admins. Information in this section is updated a few times per day. Learn more about the statistics.
AccuracyWe have received 3 reports from 3 different members within the past 12 months, not including pending responses (see below). The more responses reported, the more accurate the information.
Days Reported86 min | 175.0 mean avg | 160.0 median | 279 max days (97.4 std dev)
Pending2 responses are pending (17 min | 22.5 mean avg | 22.5 median | 28 max days waiting | 7.8 std dev) from 2 different members This only includes pending reports from users who have been active on Duotrope within the past 30 days

Other Information

Most recent response reported was received on 21 Apr 2024.
Responses have been received for submissions sent as recently as 15 Jan 2024.

Work submitted here was also submitted to...

This section is available to subscribers only. Sign up and start your free trial today!

Members accepted here also had work accepted by...

This section is available to subscribers only. Become a member and start your free trial today!

Your Submissions

This section is available to subscribers only. Join today!

Dates

Last Updated: 06 Jun 2024
Last Audited: 16 Apr 2024. (We audit each active listing twice a year. Learn more at link.)
Date Added: 30 Sep 2005

Before Submitting

We cannot guarantee that the information on this page is correct. It is not unusual for publications to evolve or close without notice. We do our best to keep up, but it isn't always possible. Duotrope listings do not imply endorsement or recommendation of the project being listed. Before submitting, you should use your own judgment to determine whether the project meets your standards.

  • Always read the full guidelines provided by the publisher.
  • Try to read at least one previous publication to get a better idea of what the editor would like to see.
  • Unless the publisher's guidelines state otherwise, always use industry standard manuscript formatting.
  • Be professional, patient, and persistent.